Vonjo (pacritinib capsules) — Cigna
Myelofibrosis (including Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, and Post-Essential Thrombocythemia Myelofibrosis)
Initial criteria
- Patient age ≥ 18 years AND
- Patient meets ONE of the following (i, ii, or iii):
- i. Platelet count < 50 × 10^9/L AND ONE of the following (a or b):
- a) Patient has higher-risk disease; OR
- b) Patient has BOTH: (1) lower-risk disease AND (2) at least one disease-related symptom (e.g., fatigue, fever, night sweats, weight loss, abdominal discomfort, splenomegaly, thrombocytosis, leukocytosis); OR
- ii. Platelet count ≥ 50 × 10^9/L AND ALL of the following (a and b):
- a) Patient has higher-risk disease; AND
- b) Patient has at least one disease-related symptom (e.g., fatigue, fever, night sweats, weight loss, abdominal discomfort, splenomegaly, thrombocytosis, leukocytosis); OR
- iii. Patient has myelofibrosis-associated anemia.
Approval duration
1 year